Ładuje się......
PHASE II STUDY OF IMATINIB MESYLATE AS THERAPY FOR PATIENTS WITH SYSTEMIC MASTOCYTOSIS
Gain-of-function D816V point mutation within the kinase domain of the transmembrane receptor KIT is found in the great majority of patients with systemic mastocytosis (SM) and is attractive therapeutic target. Twenty patients with SM were enrolled during 2003–2005 in phase II clinical trial with ima...
Zapisane w:
| Główni autorzy: | , , , , , , , |
|---|---|
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
2009
|
| Hasła przedmiotowe: | |
| Dostęp online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4184059/ https://ncbi.nlm.nih.gov/pubmed/19193436 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.leukres.2008.12.020 |
| Etykiety: |
Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!
|